Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma

Purpose To integrate standard anatomic magnetic resonance imaging in conjunction with uniformly acquired physiologic imaging biomarkers of untreated glioma with different histological grades with the goal of generating an algorithm that can be applied for patient management. Methods A total of 143 patients with previously untreated glioma were scanned immediately before surgical resection using conventional anatomical MR imaging, and with uniform acquisition of perfusion-weighted imaging, diffusion-weighted imaging, and proton MR spectroscopic imaging. Regions of interest corresponding to anatomic and metabolic lesions were identified to assess tumor burden. MR parameters that had been found to be predictive of survival in patients with grade IV glioma were evaluated as a function of tumor grade and histological sub-type. Based on these finding both anatomic and physiologic imaging parameters were then integrated to generate an algorithm for management of patients with newly diagnosed presumed glioma. Results Histological analysis indicated that the population comprised 56 patients with grade II, 31 with grade III, and 56 with grade IV glioma. Based on standard anatomic imaging, the presence of hypointense necrotic regions in post-Gadolinium T1-weighted images and the percentage of the T2 hyperintense lesion that was either enhancing or necrotic were effective in identifying patients with grade IV glioma. The individual parameters of diffusion and perfusion parameters were significantly different for patients with grade II astrocytoma versus oligodendroglioma sub-types. All tumors had regions with elevated choline to N-acetylasparate index (CNI). Lactate was higher for grade III and grade IV glioma and lipid was significantly elevated for grade IV glioma. These results were integrated into a proposed management algorithm for newly diagnosed glioma that will need to be prospectively tested in future studies. Conclusion Metabolic and physiologic imaging characteristics provide information about tumor heterogeneity that may be important for assisting the surgeon to ensure acquisition of representative histology. Correlation of these integrated MR parameters with clinical features will need to be assessed with respect to their role in predicting outcome and stratifying patients into risk groups for clinical trials. Future studies will use image directed tissue sampling to confirm the biological interpretation of these parameters and to assess how they change in response to therapy.

[1]  Michael H Lev,et al.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. , 2004, AJNR. American journal of neuroradiology.

[2]  Rebecca A Betensky,et al.  Histopathological‐Molecular Genetic Correlations in Referral Pathologist‐Diagnosed Low‐Grade “Oligodendroglioma” , 2002, Journal of neuropathology and experimental neurology.

[3]  Ying Lu,et al.  Survival analysis in patients with glioblastoma multiforme: Predictive value of choline‐to‐n‐acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume , 2004, Journal of magnetic resonance imaging : JMRI.

[4]  C R Bird,et al.  Gliomas: classification with MR imaging. , 1990, Radiology.

[5]  Glyn Johnson,et al.  Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. , 2003, AJNR. American journal of neuroradiology.

[6]  Stephen M. Smith,et al.  Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm , 2001, IEEE Transactions on Medical Imaging.

[7]  D. Vigneron,et al.  An automated technique for the quantitative assessment of 3D‐MRSI data from patients with glioma , 2001, Journal of magnetic resonance imaging : JMRI.

[8]  Susan M. Chang,et al.  Relationship of MR-derived lactate, mobile lipids, and relative blood volume for gliomas in vivo. , 2005, AJNR. American journal of neuroradiology.

[9]  D. Arnold,et al.  Proton Magnetic Resonance Spectroscopic Imaging Can Predict Length of Survival in Patients with Supratentorial Gliomas , 2003, Neurosurgery.

[10]  Nancy J Fischbein,et al.  Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. , 2005, AJNR. American journal of neuroradiology.

[11]  Inas S. Khayal,et al.  Relationship between choline and apparent diffusion coefficient in patients with gliomas , 2008, Journal of magnetic resonance imaging : JMRI.

[12]  R. Henry,et al.  Perfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas , 2006, NMR in biomedicine.

[13]  T. Mikkelsen,et al.  Correlation between Magnetic Resonance Spectroscopy Imaging and Image-guided Biopsies: Semiquantitative and Qualitative Histopathological Analyses of Patients with Untreated Glioma , 2001, Neurosurgery.

[14]  M P Carol,et al.  MR-spectroscopy guided target delineation for high-grade gliomas. , 2001, International journal of radiation oncology, biology, physics.

[15]  Usha Sinha,et al.  Relationships Between Choline Magnetic Resonance Spectroscopy, Apparent Diffusion Coefficient and Quantitative Histopathology in Human Glioma , 2000, Journal of Neuro-Oncology.

[16]  Susan M. Chang,et al.  Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors. , 2001, Magnetic resonance imaging.

[17]  P. Basser,et al.  Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. , 1996, Journal of magnetic resonance. Series B.

[18]  S. Nelson Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors , 2001, Magnetic resonance in medicine.

[19]  Susan M. Chang,et al.  Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. , 2005, AJNR. American journal of neuroradiology.

[20]  D B Vigneron,et al.  Registration of images from sequential MR studies of the brain , 1994, Journal of magnetic resonance imaging : JMRI.

[21]  Paul S Tofts,et al.  Apparent diffusion coefficient histograms may predict low‐grade glioma subtype , 2007, NMR in biomedicine.

[22]  J. M. Taylor,et al.  Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. , 2000, Journal of the National Cancer Institute.

[23]  [Correlation between magnetic resonance diffusion weighted imaging and cell density in astrocytoma]. , 2005, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[24]  Daniel Rueckert,et al.  VTK CISG Registration Toolkit: An Open Source Software Package for Affine and Nonrigid Registration of Single- and Multimodal 3D images , 2002, Bildverarbeitung für die Medizin.

[25]  G. Krol,et al.  Low-grade oligodendroglioma responds to chemotherapy , 1996, Neurology.

[26]  S. Cha,et al.  Update on brain tumor imaging: from anatomy to physiology. , 2006, AJNR. American journal of neuroradiology.

[27]  Inas S. Khayal,et al.  Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM , 2009, Journal of Neuro-Oncology.

[28]  M. Rijpkema,et al.  Characterization of oligodendrogliomas using short echo time 1H MR spectroscopic imaging , 2003, NMR in biomedicine.

[29]  J. Kurhanewicz,et al.  Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer , 2000, Magnetic resonance in medicine.

[30]  J. Petrella,et al.  MR perfusion imaging of the brain: techniques and applications. , 2000, AJR. American journal of roentgenology.

[31]  P. Warnke,et al.  MRS of oligodendroglial tumors , 2005, Neurology.

[32]  W. K. Alfred Yung PATHOLOGY AND GENETICS OF TUMOURS OF THE NERVOUS SYSTEM , 2002 .

[33]  M. Berger,et al.  Differentiation of Glioblastoma Multiforme and Single Brain Metastasis by Peak Height and Percentage of Signal Intensity Recovery Derived from Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging , 2007, American Journal of Neuroradiology.

[34]  M Takahashi,et al.  Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. , 1998, AJR. American journal of roentgenology.

[35]  Ying Lu,et al.  Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas , 2004, NMR in biomedicine.

[36]  M. Westphal,et al.  Treatment of malignant glioma: a problem beyond the margins of resection , 2001, Journal of Cancer Research and Clinical Oncology.

[37]  P. L. Lee,et al.  Magnetic resonance spectroscopy of brain tumors , 2000, Current opinion in oncology.

[38]  B. Fisher,et al.  Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Osborn Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging , 2008 .

[40]  M. Berger,et al.  Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. , 2002, Journal of neurosurgery.

[41]  Toshinori Hirai,et al.  Usefulness of diffusion‐weighted MRI with echo‐planar technique in the evaluation of cellularity in gliomas , 1999, Journal of magnetic resonance imaging : JMRI.

[42]  Carol Walker,et al.  Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype , 2007, Journal of magnetic resonance imaging : JMRI.

[43]  Soonmee Cha,et al.  Imaging Glioblastoma Multiforme , 2003, Cancer journal.

[44]  J G Pipe,et al.  In vivo MR determination of water diffusion coefficients and diffusion anisotropy: correlation with structural alteration in gliomas of the cerebral hemispheres. , 1995, AJNR. American journal of neuroradiology.

[45]  E. Shaw Looking through the retrospectoscope in the era of evidence-based medicine. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  D. Louis,et al.  Current treatment of oligodendrogliomas. , 1999, Archives of neurology.

[47]  Glyn Johnson,et al.  Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. , 2002, Radiology.

[48]  Susan M. Chang,et al.  Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy , 2008, Journal of Neuro-Oncology.